209 results on '"Jazaeri, Amir A."'
Search Results
2. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer
3. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis
4. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
5. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab
6. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.
7. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.
8. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.
9. Clinical and genomic landscape of RAS mutations in gynecologic cancers
10. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs
11. Abstract A077: The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer
12. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
13. Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer
14. Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer
15. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction
16. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
17. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma
18. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer
19. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
20. 1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
21. Transforming ovarian cancer care by targeting minimal residual disease
22. SO013/#983 Intraoperative identification of ovarian cancer during tumor reductive surgery using the hand-held masspec pen technology
23. EP159/#1534 Leveraging personalized circulating tumor DNA monitoring to predict treatment response and recurrence in high-risk endometrial cancer
24. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
25. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation
26. Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
27. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
28. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
29. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
30. Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube
31. Supplemental Tables from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
32. Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
33. Abstract 5473: Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancer
34. Supplemental Table Legends from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
35. Supplementary Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
36. Table S3 from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
37. Data from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
38. Supplementary Figure 1 from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
39. Supplementary Figure 2 from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
40. Supplementary Figure Legends from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
41. Data from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
42. Figure S1 & Figure S2 from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
43. Supplementary Methods from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
44. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
45. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies
46. Figure_S6 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
47. Supplementary Figure S1 from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
48. Data from Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer
49. Supplementary Tables from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
50. Article Figures 1-4 from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.